59128-04-0

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine-2-acetic acid, 6-bromo-, ethyl ester is used as an intermediate in the synthesis of pharmaceutical drugs for its potential biological activities. Its anti-inflammatory properties and enzyme-inhibiting capabilities contribute to the development of medications targeting various health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, Imidazo[1,2-a]pyridine-2-acetic acid, 6-bromo-, ethyl ester serves as a key component in the production of agrochemicals. Its role in inhibiting certain enzymes makes it a valuable tool in creating compounds that can protect crops from pests and diseases, thereby enhancing agricultural productivity.
Used in Research and Development:
Imidazo[1,2-a]pyridine-2-acetic acid, 6-bromo-, ethyl ester is also utilized in research and development settings. Its unique chemical structure and potential biological activities make it an interesting subject for scientific exploration, leading to the discovery of new applications and advancements in medicine and agriculture.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 13176-46-0 4-bromoethyl acetoacetate 
• 84249-14-9 2-amino-4-bromopyridine 
• 638-07-3 ethyl (2-chloroaceto)acetate 

Downstream Products

• 1017181-08-6 2-(6-bromoimidazo[1,2-a]pyridin-2-yl)ethylamine 
• 1307240-61-4 C₂₁H₂₂N₄ 

Relevant academic research and scientific papers

FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted fused tricyclic imidazole derivatives, in particular dihydro- 1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4- c']dipyridine, dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine and tetrahydro-6H- cyc

SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR1 19 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY

Disclosed is a compound which is useful as an endothelial lipase inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is aromatic carbocycle or aromatic heterocycle,Z is —NR5—, —O— or —S—,R5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or the like,R1 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like,R2 and R3 are each independently hydrogen, halogen, hydroxy or the like,R4 is a group represented by the formula: —(CR6R7)n-R8, wherein R6 and R7 are each independently hydrogen, halogen, hydroxy or the like, n is an integer of 0 to 3, R8 is carboxy, cyano, substituted or unsubstituted alkyl or the like, Rx is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like,m is an integer of 0 to 3.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below:

DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE

The present invention provides the compounds represented by formula (I): (I) or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being usefull for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS

The current invention relates to compounds of the formula:(Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.